Total Payments
$3.8M
2024 Payments
$524,879
Companies
60
Transactions
4,889
Medicare Patients
6,793
Medicare Billing
$894,531
Payment Breakdown by Category
Other$2.8M (74.2%)
Consulting$435,895 (11.4%)
Travel$366,588 (9.6%)
Food & Beverage$103,861 (2.7%)
Research$79,201 (2.1%)
Education$822.09 (0.0%)
Gifts$150.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.8M | 973 | 72.1% |
| Consulting Fee | $435,895 | 136 | 11.4% |
| Travel and Lodging | $366,588 | 1,079 | 9.6% |
| Food and Beverage | $103,861 | 2,616 | 2.7% |
| Unspecified | $79,201 | 32 | 2.1% |
| Honoraria | $53,950 | 17 | 1.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $25,560 | 10 | 0.7% |
| Education | $822.09 | 25 | 0.0% |
| Gift | $150.00 | 1 | 0.0% |
Payments by Type
General
$3.7M
4,857 transactions
Research
$79,201
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $563,235 | 617 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $356,722 | 458 | $0 (2024) |
| GENZYME CORPORATION | $314,049 | 286 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $278,999 | 298 | $0 (2024) |
| Celgene Corporation | $272,653 | 244 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $270,197 | 197 | $0 (2024) |
| ABBVIE INC. | $238,004 | 467 | $0 (2024) |
| Amgen Inc. | $230,682 | 309 | $0 (2024) |
| Janssen Biotech, Inc. | $211,697 | 449 | $0 (2024) |
| UCB, Inc. | $201,325 | 265 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $524,879 | 643 | UCB, Inc. ($94,485) |
| 2023 | $552,339 | 676 | Lilly USA, LLC ($105,275) |
| 2022 | $503,089 | 684 | GENZYME CORPORATION ($97,182) |
| 2021 | $227,602 | 371 | Lilly USA, LLC ($40,711) |
| 2020 | $195,631 | 266 | Lilly USA, LLC ($29,515) |
| 2019 | $465,817 | 642 | Novartis Pharmaceuticals Corporation ($94,563) |
| 2018 | $648,412 | 752 | Celgene Corporation ($113,337) |
| 2017 | $703,487 | 855 | Regeneron Healthcare Solutions, Inc. ($124,933) |
All Payment Transactions
4,889 individual payment records from CMS Open Payments — Page 1 of 196
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: Immunology | ||||||
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,240.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $69.90 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $62.97 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Lilly USA, LLC | TALTZ (Drug), ZEPBOUND, EBGLYSS | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $275.40 | General |
| 12/13/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $34.58 | General |
| Category: Immunology | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.04 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $3.73 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $180.48 | General |
| Category: Immunology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $150.71 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $17.86 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Inflammation | ||||||
| 12/06/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $54.55 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $714.86 | General |
| 12/05/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $147.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $42,256 | 4 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $18,379 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,217 | 3 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $3,324 | 1 |
| CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT SATISFACTION AMONG PSORIASIS PATIENTS TREATED WITH COSENTYX (SECUKINUMAB) | Novartis Pharmaceuticals Corporation | $2,500 | 1 |
| CC-10004-PSOR-008 CC-10004-PSOR-009 | Celgene Corporation | $1,488 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,069 | 2 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $929.99 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $525.78 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $347.91 | 14 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $100.00 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $65.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,780 | 3,920 | $476,749 | $223,381 |
| 2022 | 23 | 1,883 | 3,757 | $513,837 | $236,622 |
| 2021 | 24 | 1,685 | 3,210 | $622,114 | $226,891 |
| 2020 | 24 | 1,445 | 2,830 | $579,552 | $207,636 |
Total Patients
6,793
Total Services
13,717
Medicare Billing
$894,531
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 385 | 690 | $103,217 | $47,799 | 46.3% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 29 | 35 | $38,468 | $20,253 | 52.6% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 37 | 40 | $46,585 | $18,054 | 38.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 179 | 216 | $38,280 | $17,785 | 46.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 193 | 317 | $36,531 | $16,640 | 45.5% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 33 | 36 | $25,618 | $13,703 | 53.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 91 | 127 | $26,821 | $13,267 | 49.5% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 169 | 299 | $21,638 | $11,312 | 52.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 44 | 75 | $21,697 | $10,922 | 50.3% |
| 17314 | Removal and microscopic exam of growth of trunk, arms, or legs, each additional stage, 1-5 tissue blocks | Office | 2023 | 23 | 27 | $18,445 | $9,866 | 53.5% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 27 | 32 | $23,393 | $7,770 | 33.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 160 | 1,193 | $14,020 | $7,173 | 51.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 93 | 156 | $14,768 | $6,811 | 46.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 73 | 73 | $13,507 | $5,923 | 43.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 55 | 90 | $7,859 | $4,144 | 52.7% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 27 | 29 | $6,235 | $3,017 | 48.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $5,740 | $2,781 | 48.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 18 | 31 | $6,157 | $2,680 | 43.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 20 | 60 | $2,403 | $1,240 | 51.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 44 | 106 | $2,524 | $1,226 | 48.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 19 | 25 | $2,447 | $820.78 | 33.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 40 | 242 | $395.26 | $193.74 | 49.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 401 | 710 | $112,211 | $50,878 | 45.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 203 | 249 | $46,724 | $20,681 | 44.3% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 29 | 34 | $40,146 | $19,876 | 49.5% |
About Paul Yamauchi, M.D., PHD
Paul Yamauchi, M.D., PHD is a Dermatology healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1720074537.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Paul Yamauchi, M.D., PHD has received a total of $3.8M in payments from pharmaceutical and medical device companies, with $524,879 received in 2024. These payments were reported across 4,889 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.8M).
As a Medicare-enrolled provider, Yamauchi has provided services to 6,793 Medicare beneficiaries, totaling 13,717 services with total Medicare billing of $894,531. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Santa Monica, CA
- Active Since 09/27/2005
- Last Updated 11/28/2016
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1720074537
Products in Payments
- Otezla (Drug) $460,038
- TALTZ (Drug) $443,869
- COSENTYX (Biological) $331,918
- DUPIXENT (Biological) $326,390
- TREMFYA (Drug) $249,360
- DUPIXENT DUPILUMAB INJECTION (Biological) $175,032
- Tremfya (Drug) $143,118
- Bimzelx (Biological) $97,173
- CIBINQO (Drug) $93,199
- Sotyktu (Drug) $90,566
- Cimzia (Drug) $85,691
- ADBRY (Biological) $84,602
- SKYRIZI (Biological) $78,434
- STELARA (Biological) $71,777
- OLUMIANT (Drug) $68,288
- ATOPIC DERMATITIS - DISEASE (Drug) $65,920
- RINVOQ (Biological) $65,691
- Humira (Biological) $53,668
- OPZELURA (Drug) $48,561
- VTAMA (Drug) $47,714
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Santa Monica
Dr. Daniel Behroozan, M..d, M..D
Dermatology — Payments: $166,937
Dermatology $166,937
Dr. Stefani Kappel, M.d,, M.D,
Dermatology — Payments: $80,886
Dermatology $80,886
Karyn Grossman, M.d, M.D
Dermatology — Payments: $7,696
Dermatology $7,696
Dr. Adriana Schmidt, Md, MD
Dermatology — Payments: $6,093
Dermatology $6,093
Jackelyn Beshir, M.d, M.D
Dermatology — Payments: $5,550
Dermatology $5,550
Parrish Sadeghi, Md, MD
Dermatology — Payments: $4,986
Dermatology $4,986